Leiter Amanda, Charokopos Antonios, Bailey Stacyann, Gallagher Emily J, Hirsch Fred R, LeRoith Derek, Wisnivesky Juan P
Division of Endocrinology, Diabetes, and Bone Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Transl Lung Cancer Res. 2021 Nov;10(11):4200-4208. doi: 10.21037/tlcr-21-601.
Diabetes is a well-established risk factor for many cancers, but its relationship with lung cancer incidence remains unclear. In this study, we aimed to assess if diabetes is independently associated with lung cancer risk and histology subtype among participants in a screening study.
In a retrospective cohort study using data from the Prostate, Lung, Colorectal, and Ovarian (PLCO) study, we assessed the association of self-reported diabetes with lung cancer incidence using Poisson regression while adjusting for other established risk factors in the PLCOM2012, a validated lung cancer prediction model. The adjusted association of diabetes and lung cancer cell type was evaluated using nominal regression. Stratified analyses were also conducted according to sex, smoking history, and body mass index categories.
Overall, 140,395 participants were included in our analysis. Diabetes was not significantly associated with lung cancer incidence [incidence rate ratio (IRR): 1.03, 95% confidence interval (CI): 0.91-1.17]. Similarly, stratified analyses also did not show significant associations between diabetes and lung cancer risk (all P values >0.05). We found no significant difference in the distribution of lung cancer histology in participants with . without diabetes (P=0.30).
Diabetes was not an independent risk factor for lung cancer in a large cohort of PLCO participants. We did not observe differences in histology according to diabetes status. These results suggest that patients with diabetes do not need more aggressive lung cancer screening. Future research including more detailed metabolic parameters may further elucidate the relationship between metabolic disease and lung cancer risk.
糖尿病是多种癌症公认的危险因素,但其与肺癌发病率的关系仍不明确。在本研究中,我们旨在评估在一项筛查研究的参与者中,糖尿病是否与肺癌风险及组织学亚型独立相关。
在一项回顾性队列研究中,我们使用前列腺、肺、结肠和卵巢(PLCO)研究的数据,在调整PLCOM2012(一种经过验证的肺癌预测模型)中的其他既定风险因素后,采用泊松回归评估自我报告的糖尿病与肺癌发病率之间的关联。使用名义回归评估糖尿病与肺癌细胞类型的调整后关联。还根据性别、吸烟史和体重指数类别进行了分层分析。
总体而言,140,395名参与者纳入了我们的分析。糖尿病与肺癌发病率无显著关联[发病率比(IRR):1.03,95%置信区间(CI):0.91 - 1.17]。同样,分层分析也未显示糖尿病与肺癌风险之间存在显著关联(所有P值>0.05)。我们发现糖尿病患者与非糖尿病患者的肺癌组织学分布无显著差异(P = 0.30)。
在大量PLCO参与者队列中,糖尿病不是肺癌的独立危险因素。我们未观察到根据糖尿病状态在组织学上的差异。这些结果表明,糖尿病患者无需进行更积极的肺癌筛查。包括更详细代谢参数的未来研究可能会进一步阐明代谢疾病与肺癌风险之间的关系。